Pages that link to "Q34682814"
Jump to navigation
Jump to search
The following pages link to Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial (Q34682814):
Displaying 50 items.
- Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (Q24193064) (← links)
- Antioxidants and other pharmacological treatments for Friedreich ataxia (Q24200235) (← links)
- Idebenone for the treatment of Duchenne muscular dystrophy (Q24201942) (← links)
- Idebenone for the treatment of Duchenne muscular dystrophy (Q24236662) (← links)
- Antioxidants and other pharmacological treatments for Friedreich ataxia (Q24240370) (← links)
- Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier? (Q26853254) (← links)
- Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment (Q28078384) (← links)
- Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia (Q28474531) (← links)
- Coenzyme Q10 and Neurological Diseases (Q30440307) (← links)
- Prevalence of ataxia in children: a systematic review (Q30560727) (← links)
- Common data elements for clinical research in Friedreich's ataxia. (Q30581588) (← links)
- Deferiprone targets aconitase: implication for Friedreich's ataxia treatment (Q33344109) (← links)
- Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen (Q33496330) (← links)
- Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients: cellular model of pathology (Q33525513) (← links)
- Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency (Q33527398) (← links)
- Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation (Q33555894) (← links)
- Neuroferritinopathy: a new inborn error of iron metabolism (Q33685685) (← links)
- Therapeutic approaches to spinal and bulbar muscular atrophy (Q33701169) (← links)
- Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. (Q33701891) (← links)
- Past, Present and Future Therapeutics for Cerebellar Ataxias (Q33836935) (← links)
- Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study (Q33968480) (← links)
- Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts (Q34053510) (← links)
- Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities (Q34076650) (← links)
- Longitudinal tracking of gait and balance impairments in cerebellar disease (Q34126414) (← links)
- Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies (Q34152110) (← links)
- Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design (Q34197370) (← links)
- Clinical data and characterization of the liver conditional mouse model exclude neoplasia as a non-neurological manifestation associated with Friedreich's ataxia. (Q34317949) (← links)
- The neuro-ophthalmology of mitochondrial disease (Q34338783) (← links)
- Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia (Q34373154) (← links)
- Pharmacological treatments for Friedreich ataxia. (Q34538823) (← links)
- Co-enzyme Q10 and idebenone use in Friedreich's ataxia (Q34654338) (← links)
- Clinical experience with high-dose idebenone in Friedreich ataxia (Q34778763) (← links)
- Consensus clinical management guidelines for Friedreich ataxia (Q34789144) (← links)
- Diagnosis and treatment of Friedreich ataxia: a European perspective (Q34974299) (← links)
- Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone (Q35045060) (← links)
- Consensus paper: management of degenerative cerebellar disorders (Q35129909) (← links)
- Treatment of Leber hereditary optic neuropathy (Q35452117) (← links)
- Mitochondrial energetics and therapeutics (Q35632864) (← links)
- Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases (Q35958359) (← links)
- Stable isotopes and LC-MS for monitoring metabolic disturbances in Friedreich's ataxia platelets (Q36207736) (← links)
- Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia (Q36488119) (← links)
- Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. (Q36760861) (← links)
- Drug development for rare mitochondrial disorders (Q36762826) (← links)
- Review of clinical trials for mitochondrial disorders: 1997-2012. (Q36762846) (← links)
- The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation (Q36775301) (← links)
- Unanswered questions in Friedreich ataxia (Q36907500) (← links)
- Childhood ataxia: clinical features, pathogenesis, key unanswered questions, and future directions (Q36964084) (← links)
- How mitochondrial dysfunction affects zebrafish development and cardiovascular function: an in vivo model for testing mitochondria-targeted drugs. (Q36965904) (← links)
- Neurodegeneration in Friedreich's ataxia: from defective frataxin to oxidative stress (Q37052023) (← links)
- Drug Insight: antioxidant therapy in inherited ataxias (Q37078851) (← links)